Familial hypercholesterolemia. A report of a WHO consultation. WHO , Geneva, Switzerland, 1998.
Wierzbicki AS, Humphries SE , Minhas R, on behalf of the Guideline Development Group. Familial hypercholesterolaemia:summary of NICE guidance. BMJ 2008; 337: a1095.
Reiner Ž, Catapano AL, De Backer G, et al. ESC /EAS guidelines for management of dyslipidemias of the European Society of Cardiology (ESC ) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818.
Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer and coronary mortality in statin-treated patients with heterozygous hypercholesterolemia: a prospective registry study. Eur Heart J 2008; 29: 2625–2633.
Watts GF, Lewis B, Sullivan DR . Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nature Clin Pract Cardiovasc Med 2007; 4: 404–405.
Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173(1): 55–68.
Brown MS, Goldstein JL . How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984; 251(3): 52–60.
Innerarity TL , Weisgraber KH , Arnold KS , et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84: 6919–6923.
Abifadel M, Varret M, Rab JP , et al. Mutations in PCSK 9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34: 154–156.
Abifadel M, Rabes JP , Devillers M, et al. Mutations and polymorphisms in the Proprotein Convertase Subtilin Kexin 9 (PCSK 9)Gene in cholesterol metabolism and disease. Hum Mutat 2009; 30: 520–529.
Varret M, Abifadel M, Rabes JP , et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Gen 2008;78: 1–13.
Chmara M, Wasąg B, Żuk J, et al. Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations. Limon J Appl Genet 2010; 51(1): 95–106
Huang CC , Fornage M, Lloyd-Jones DM, et al. Longitudinal association of PCSK 9 sequence variations with low-density lipoprotein cholesterol levels the coronary artery risk development in young adults study. Circ Cardiovasc Genet 2009; 2: 354–361.
Austin MA, Hutter CM, Zimmern RL , et al. Familial hypercholesterolemia and coronary heart disease: a H uGE association review. Am J Epidemiol 2004; 160: 421–429.
Vermissen J, Oosterveer DM, Yazdanpanach M, et al. Efficacy of statins in familial hypercholesterolemia: a long term cohort study. BMJ 2008; 337: a2423.
Pijlman AH, Huijgen R, Verhagen SN , et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia:a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209: 189–194.
Ito MK, McGowan MP, Moriaty PM. Management of familial hyperlipidemias in adult patients. Recommendations from National Lipid Association Expert Panel of Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(Suppl.): S38–S45.
Leren TP , Finborud TH , Manshaus TE , et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Commun Genet 2008; 11: 26–35.
Hegele RA. Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia. Genome (Canada) 2006; 49: 343–350.
Goldberg AC, Hopkins PN , Toth PP , et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adults patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
and adults patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.J Clin Lipidol 2011; 5(3 Suppl.): S1–S8.
J Clin Lipidol 2011; 5(3 Suppl.): S1–S8.
21. Nicholls P, Young I, Lyttle K, et al. Screening for familial hypercholesterolaemia. Early identification and treatment of patients
is important. BMJ 2001; 322: 1062.
22. Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol
2008; 102: 1187–1193.
23. Datta BN, McDowell IF , Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia.
Curr Opin Lipidol 2010; 21(4): 266–271
24. Defesche JC . Defining the challenges of FH Screening for familial hypercholesterolemia. J Clin Lipidol 2010; 4(5): 338–341.
25. Kusters DM, Homsma SJ , Hutten BA, et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy.
Neth J Med 2010; 68(1): 299–303.
26. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK 9 on LDL cholesterol. N Engl J Med 2012;
366: 1108–1118.
27. Giugliano RP , Desai NR , Kohli P, et al. for the LAPL ACE -TI MI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal
antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients withhypercholesterolaemia
(LAPL ACE -TI MI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; doi: 10.1016/S0140-
6736(12)61770-X.
28. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody
to proprotein convertase subtilisin/Kexin Type 9 Serine Protease in Patients with heterozygous familial hypercholesterolemia
the Reduction of LDL -C With PCSK 9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD )